GlassScriptPhysician profile
Marta Gryniuk
NPI 1538164595
$3,937.79
in general payments reported to CMS, 2019-2025
35 companies · $914 in 2025
The $914 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.60 · 2020: $30.88 · 2021: $44.52 · 2022: $415 · 2023: $995 · 2024: $1,446 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,355.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $653.34 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $474.79 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $391.15 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $371.07 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $235.55 | 2022-2025 | |
| Dexcom, INC. | $212.31 | 2023-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $134.62 | 2022-2025 | Verquvo, Belsomra |
| Exact Sciences Corporation | $115.51 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $113.60 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Phathom Pharmaceuticals, INC. | $109.96 | 2024 | Voquezna |
| Pfizer INC. | $95.30 | 2022-2024 | |
| Glaxosmithkline, LLC. | $86.09 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.76 | 2023-2025 | Xifaxan, Trulance |
| Esperion Therapeutics, INC. | $81.68 | 2023-2025 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $80.99 | 2023-2024 | Rexulti, Nuedexta |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $75.50 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.36 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $58.27 | 2023-2024 | Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.02 | 2022-2024 | Jardiance |
| Medtronic Minimed, INC. | $47.98 | 2019-2020 | |
| Inspire Medical Systems, INC. | $42.54 | 2024 | Inspire |
| Amgen INC. | $42.33 | 2024 | Repatha, Otezla |
| Astellas Pharma US INC | $41.68 | 2024 | Veozah |
| Dynavax Technologies Corporation | $33.86 | 2024 | Heplisav-B |
| Ironshore Pharmaceuticals INC. | $33.21 | 2023-2024 | Jornay Pm |
| Biohaven Pharmaceutical Holding Company LTD. | $30.06 | 2022 | |
| Axsome Therapeutics, INC. | $27.08 | 2023 | Auvelity |
| Verona Pharma, INC. | $25.75 | 2025 | Ohtuvayre |
| Itf Therapeutics LLC | $21.25 | 2025 | |
| Krystal Biotech INC | $20.97 | 2023 | Vyjuvek |
| Boston Scientific Corporation | $16.47 | 2023 | Watchman Access System |
| Amneal Pharmaceuticals LLC | $16.18 | 2023 | Lyvispah |
| Lucid Diagnostics INC. | $15.64 | 2024 | |
| Scynexis, INC. | $15.55 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.37 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marta Gryniuk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.